TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04222790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialic gangliosides
Description: The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
Study: NCT02361593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without a transparent cap
Description: Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
Study: NCT02323893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG
Study: NCT02930564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDED + milk fat and gluten
Description: CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
Study: NCT03702725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
Study: NCT06190483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 5 Mg Oral Tablet
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 5 Mg Oral Tablet
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 50 Mg Oral Tablet
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 50 Mg Oral Tablet
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
Study: NCT01725165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo clinical observation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo standard maintenance therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04122196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
Study: NCT02406846

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT02421198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YMCA Family Diabetes Prevention Program (YFDPP)
Description: 12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YMCA Family Diabetes Prevention Program (YFDPP)
Description: 12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
Study: NCT02113202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence endoscopy platform
Description: A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence endoscopy platform
Description: A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence endoscopy platform
Description: A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
Study: NCT02054702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Up to 20 mg/day, once daily dose, tablets, orally
Study: NCT02310594

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo blood sample collection

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02337127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine, 100mg/day, per os
Study: NCT04222790

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
Study: NCT03196570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Contact Control
Description: Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
Study: NCT04249830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS TCR α/β Reagent Kit and CliniMACS CD19
Description: The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS TCR α/β Reagent Kit and CliniMACS CD19
Description: The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
Study: NCT01469650

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferal
Description: 400 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 800 IU/day D3
Study: NCT00753389

Intervention type: OTHER
Intervention: None (anesthesia)
Description: anesthesia
Study: NCT00440453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Nutritional therapy by dietician
Study: NCT01364532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transulnar arterial access
Description: Transulnar arterial access in coronary angiography, ad-hoc or elective PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transradial arterial access
Description: Transradial arterial access for coronary angiography,ad-hoc or elective PCI
Study: NCT02466503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhaled corticosteroid, pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Inhaled corticosteroid, pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol (as xinafoate)
Description: Beta-agonist, LABA, pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol (as xinafoate)
Description: Beta-agonist, LABA, pMDI
Study: NCT02588287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws for tenofovir PK, renal function
Study: NCT03081169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium 150 MG/ML Prefilled Syringe
Description: The same drugs and dosages will be used in both groups, with only the timing being different

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium 150 MG/ML Prefilled Syringe
Description: The same drugs and dosages will be used in both groups, with only the timing being different

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The same drugs and dosages will be used in both groups, with only the timing being different

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The same drugs and dosages will be used in both groups, with only the timing being different
Study: NCT04828967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis is added to the conventional group
Study: NCT01697046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada and Isentress
Description: Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days.
Study: NCT01614223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACP
Description: Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid (celestone) injection
Description: Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
Study: NCT03179267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNAP40
Description: SNAP40 ambulatory monitoring device
Study: NCT03010501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Energy Density
Description: Food Energy density manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Energy Density
Description: Food Energy density manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Energy Density
Description: Food Energy density manipulated
Study: NCT02430233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone 400 mg (Utrogestan)
Description: participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
Study: NCT02272101

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D versus placebo
Description: Cross-over design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D versus placebo
Description: Cross-over design
Study: NCT03796663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Parenting Program
Description: The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting Program
Description: The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATCH BPT Program
Description: The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
Study: NCT00462462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol 96% Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol 98% Solution
Study: NCT04507321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Oral tablet
Description: GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK3640254 intravenous infusion
Description: \[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK3640254 powder
Description: \[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
Study: NCT00859846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial line placement
Description: The following measures will be collected and compared.~1. Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~2. number of attempts, defined as forward advancements of needle, required to cannulate the artery.~3. number of separate skin punctures.~4. number of arteries into which entry is attempted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial line placement
Description: The following measures will be collected and compared.~1. Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~2. number of attempts, defined as forward advancements of needle, required to cannulate the artery.~3. number of separate skin punctures.~4. number of arteries into which entry is attempted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial line placement
Description: The following measures will be collected and compared.~1. Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~2. number of attempts, defined as forward advancements of needle, required to cannulate the artery.~3. number of separate skin punctures.~4. number of arteries into which entry is attempted.
Study: NCT03561207

Intervention type: DIAGNOSTIC_TEST
Intervention: EV3D Assay
Description: The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.